genome sequences of targeted HPV types retrieved from the GenBank database (accession nos. X55964, EF117890, EF117891, EF362754, EF362755, X74473, AB211993, X55965, U37537, and AB361563) were aligned using the MAFFT v6.846 algorithm (34) , as described previously (35) . After evaluating the multiple alignment of complete HPV2, HPV27, and HPV57 genome sequences, the HPV L2 gene was selected as the most appropriate target region. Type-specific RT-PCR primers and hydrolysis probes (Table  1) , allowing amplification of 144-, 145-, and 157-bp fragments of the respective L2 genes, were designed using Vector NTI Advance v11 software (Thermo Fisher Scientific, Carlsbad, CA) and subsequently revised for thermodynamic features of primer/probe and the potential of binding to non-targeted DNA sequences using the web-based applications NetPrimer (PREMIER Biosoft International, Palo Alto, CA), Primer3Plus (36) , BLAST (National Center for Biotechnology Information, US National Library of Bethesda, MD), and MFEprimer-2.0 (37) . As shown in Table 1 , primer combinations 2-27F(59.8)/2R(59.2), 2-27F(59.8)/27R(57.6), and 57F(57.8)/57R(57. 9) were used to amplify targeted regions of HPV2, HPV27, and HPV57, respectively. Type-specific hydrolysis probes-HPV2-P0(68.25), HPV27-P0(68.55), and HPV57-P0(65.34) (Table 1 )-hybridized completely (100%) only with targeted HPV types and presented several (up to seven) nucleotide mismatches with non-targeted nucleotide sequences, enabling reliable discrimination between infections with HPV2, HPV27, and HPV57 (Fig. 1) .
In order to optimize the amplification conditions and to evaluate the sensitivity, specificity, and efficiency of the HPV2/27/57 multiplex RT-PCR, plasmid standards containing viral sequences with binding sites of type-specific primers and probes were generated as follows. Three respective sense primers-HPV2-L2-FW (5'-CCCATTGTGTGATATTTGC-3'), HPV27-L2-FW (5'-CACC-CTCATTGGCTTATTA-3'), and HPV57-L2-FW (5'-CGTCTGCTGCAG-TAGTGTAC-3')-were used in combination with the consensus antisense primer HPV2,27,57-L2-RW (5'-TGACATAGACATCCGTACT-GA-3') to amplify 1,730-, 1,599-, and 1,580-bp fragments of HPV2, 27, and 57, respectively. The obtained PCR amplicons were puri- , and HPV57 type-specific hydrolysis probes to respective L2 gene sequences. The figure was obtained from a multiple sequence alignment of type-specific hydrolysis probes and complete genome sequences of respective HPV types that were retrieved from the GenBank database (GenBank accession numbers are provided next to all full genome sequences included). Dots show the nucleotide positions of hydrolysis probes identical to the targeted regions of HPV2, HPV27, and HPV57.
Legend/abbreviations: a Nucleotide positions of primers and probes were compared to HPV2, HPV27, and HPV57 reference sequences (GenBank accession nos. X55964, X74473, and X55965, respectively), which were adjusted to start with a first nucleotide of respective E6 genes. , and 2.59 × 10 10 copies of HPV2, 27, and 57 DNA per µl, respectively, and were subsequently serially diluted, as described previously (38) . All commercially available reagents were used according to the manufacturers' instructions.
HPV2-P0(68.25)
The Table 1 ), real-time monitoring of the fluorescent signal was performed on 610, 560, and 530 nm channels, indicating amplification of HPV2, HPV27, and HPV57, respectively. In addition, due to the slight overlap of the emission spectra of the dyes, the software's color compensation function was applied during the analysis of all RT-PCR experiments. Moreover, the specificity of all HPV2/27/57 RT-PCR amplicons was further confirmed by direct Sanger sequencing with the same primers as used for the RT-PCR, as described previously (39) .
The performance of the HPV2/27/57 multiplex RT-PCR in the routine clinical laboratory setting was evaluated on 35 fresh-frozen tissue samples, obtained from the same number of children, 2 to 18 years old, with common warts (10 samples) and anogenital warts (25 samples) that were referred to the Laboratory for Molecular Microbiology and Slovenian HIV/AIDS Reference Centre, Institute of Microbiology and Immunology, Faculty of Medicine, University of Ljubljana, in the last 10 years.
The tissue samples were first processed for total DNA extraction with a QIAamp DNA Mini Kit (Qiagen) and spectrophotometric analysis of eluted DNA, as described previously (40) . Up to 100 ng of extracted DNA was used for downstream PCR analyses. To detect low-risk Alpha-PVs associated with various mucosal and cutaneous warts, a PCR protocol targeting an approximately 190-bp fragment of the E1 gene of HPV2, HPV3, HPV6, HPV7, HPV10, HPV11, HPV13, HPV27, HPV28, HPV29, HPV32, HPV40, HPV42, HPV43, HPV44, HPV57, HPV74, HPV77, HPV78, HPV91, HPV94, HPV117, and HPV125 was performed, as described elsewhere (31), and HPV types were subsequently determined by direct Sanger sequencing of all eligible PCR products, as described previously (39) . Furthermore, a FRET-based HPV6/11 RT-PCR (40), enabling reliable detection and differentiation of 25.3, 42.9, and 43.4 DNA copies of HPV11 and prototypic and non-prototypic HPV6 genomic variants, respectively, was additionally used to determine the causal agents of condylomata acuminata.
Results
Testing replicates of 10-fold serially diluted plasmids containing targeted fragments of HPV2, HPV27, and HPV57 in concentrations spanning from 1 × 10 8 to 1 × 10 DNA copies per reaction, in a background of 100 ng of Human Genomic DNA, showed that the HPV2/27/57 multiplex RT-PCR is able to detect at least 10 viral copies of each targeted HPV type per a single reaction ( Fig. 2; A1, B1,  C1 ). The dynamic range of HPV2/27/57 multiplex RT-PCR was seven orders of magnitude for all targeted HPV types, enabling reliable discrimination of 10 to 10 8 viral genome equivalents per a single reaction. The correlation coefficients (R²) of standard curves estimated from amplification of plasmid standards containing fragments of HPV2, HPV27, and HPV57 were 0.999, 0.999, and 0.998, respectively. The amplification efficiencies (E) were estimated at 95.2, 92.0, and 92.2% for HPV2, HPV27, and HPV57, respectively, and the performance of the HPV2/27/57 multiplex RT-PCR was not affected by the presence of background human genomic DNA. In addition, as shown in Fig. 2 (A2, B2, and C2) , no cross-reactivities of HPV27/HPV57, HPV2/HPV57, and HPV2/HPV27 were observed when using primer/probe combinations targeting HPV2, HPV27, and HPV57, respectively. Moreover, all three primer/probe combinations were efficient in amplifying 500 copies of targeted DNA in a background of 1 × 10 8 , 1 × 10 7 , 500, 100, and 10 copies of nontargeted viral DNA per reaction ( Fig. 2; A3, B3, C3 ).
As shown in Table 2 , the targeted fragment of human betaglobin gene was successfully amplified from all 35 DNA isolates obtained from fresh-frozen tissue specimens of condylomata acuminata and verrucae vulgares. HPV2, HPV27, and HPV57 were detected in 7/10 (70.0%) tested verrucae vulgares using both Lowrisk Alpha-PV PCR and HPV2/27/57 multiplex RT-PCR; and in all seven HPV-positive cases both PCRs identified the same HPV type (Table 2 ; samples nos. 1-7). The results of both PCRs were additionally completely concordant when testing different warts from the anogenital region, since HPV2, HPV27, and HPV57 were detected in 13/25 (52.0%) tested samples, irrespective of the method used. Furthermore, in seven condylomata acuminata that were previously HPV6-positive using Low-risk Alpha-PV PCR, the presence of HPV6 was confirmed with the HPV6/11 RT-PCR and all seven samples tested HPV2/27/57-negative using the HPV2/27/57 multiplex RT-PCR (Table 2 , samples nos. [24] [25] [26] [27] [28] [29] [30] . Using the PCR protocols mentioned above, Alpha-PV DNA was absent in three and five samples of tested verrucae vulgares and condylomata acuminata, respectively ( , 500, 100, and 10 viral copies of HPV27/HPV57, HPV2/HPV57, and HPV2/HPV27 per reaction, respectively.
Discussion
Verrucae vulgares or common warts constitute the most frequent benign HPV-associated skin condition, especially in children and immunosuppressed patients (5, 6) . Most common warts resolve spontaneously within several months, have a benign nature, and are successfully treated with various regimens or procedures such as cryotherapy, salicylic acid, and topical and intralesional immunotherapy (42) . Although they are more prevalent in children, the etiology of common warts does not differ according to patient's age group; common warts are most frequently associated with infections with three HPV genotypes: HPV2, HPV27, and HPV57 (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) . In contrast, the etiology of warts found in the anogenital region differs between children and adults. Sexually transmitted HPV6 and HPV11 are by far the most common HPV types identified in warts in the anogenital region of adult patients of both genders because the great majority of these warts are indeed condylomata acuminata and only rarely verrucae vulgares (11, 12, (16) (17) (18) 43) . In contrast, up to two-thirds of warts found in the anogenital region of children are actually verrucae vulgares, which are most frequently etiologically associated with infections with HPV2, HPV27, and HPV57 (13) (14) (15) 19) . Even though both HPV6 and HPV11 are associated with a small proportion of warts found in the anogenital region of children, the routes of transmission of condylomata acuminata in this population are mostly non-sexual, including vertical transmission and indirect transmission through contaminated objects or surfaces, and are only rarely a result of sexual abuse (13) (14) (15) 19) .
For years, warts identified in the anogenital region of patients of all ages (including children) referred to our molecular diagnostics laboratory had first been tested for the presence of Alpha-PVs using the Low-risk Alpha-PV PCR (31), with a turnaround time of at least 370 min, including the analysis of PCR products using direct Sanger sequencing. Although very sensitive and specific, Low-risk Alpha-PV PCR is quite laborious, has a long turnaround time, and is therefore inappropriate for use in a routine clinical laboratory setting. The newly developed HPV2/27/57 multiplex RT-PCR is able to specifically detect at least 10 viral copies per a single reaction of each targeted HPV type, irrespective of potentially high concentrations of other HPV types present in a sample (concurrent HPV infection with several HPV types), and its performance is also not affected by the presence of a high background of human genomic DNA. Furthermore, HPV2/27/57 multiplex RT-PCR has a relatively short turnaround time of approximately 70 min, rendering it appropriate for routine diagnostics. Therefore, when testing warts found in the anogenital region of a child, the HPV2/27/57 multiplex RT-PCR recently became the method of choice in our laboratory. HPV2/27/57-negative children's warts are subsequently tested for the presence of HPV6 and HPV11 using the HPV6/11 RT-PCR (40), and when both of these RT-PCRs are negative the conventional Low-risk Alpha-PV PCR is used as a supportive method due to its ability to detect several other cu- taneous and mucosal wart-associated Alpha-PV types (31). In contrast, because more than 90% of warts identified in the anogenital region of adult patients are etiologically associated with sexually transmitted HPV6 and HPV11 (11, 12, (16) (17) (18) 43) , when testing this patient population the method of choice in our laboratory is the HPV6/11 RT-PCR (40), followed in the case of a negative result by HPV2/27/57 multiplex RT-PCR and Low-risk Alpha-PV-PCR (31). Alpha-PV-negative wart tissue samples are additionally tested in our laboratory for research purposes only for the presence of several Gamma-and Mu-PVs that cause sporadic cutaneous warts (7, 9, 11, 12, 26, 44, 45) . All HPV-negative warts identified in the anogenital region of patients of all ages and both sexes are additionally tested in our laboratory for the presence of molluscum contagiosum virus (MCV) using the MCV FRET RT-PCR (45) because, due to the similar clinical appearance of lesions, up to 10% of molluscum contagiosum lesions can be misdiagnosed as condylomata acuminata or verrucae vulgares and vice versa (45) (46) (47) (48) .
Because HPV2, HPV27, and HPV57 are associated with a large fraction of verrucae vulgares in immunosuppressed patients, in which they often occur ubiquitously and confluently, Senger et al. provided a basis for the development of virus-like particle-based vaccines against cutaneous Alpha-PVs (49, 50). Our HPV2/27/57 multiplex RT-PCR could therefore be additionally applicable for large epidemiological studies of the etiology of common warts in immunosuppressed patients and for potential evaluation of the efficacy of the future vaccine(s) against HPV2, HPV27, and HPV57.
In contrast to previously described conventional PCRs (23-30), which amplify up to 835-bp fragments of HPV DNA, the HPV2/27/57 multiplex RT-PCR targets significantly shorter HPV DNA fragments (144-157-bp), also rendering it very appropriate for HPV typing in archival tissue specimens (51) . Furthermore, the majority of conventional broad-spectrum PCRs are not suitable for detecting viral targets present in low concentrations, and Sanger sequencing of PCR products hinders the identification of concurrent HPV infections. Namely, in sporadic cases of common warts concurrent infections with two or more HPV types can be identified, including their well-known etiological agents, such as HPV1, HPV2, HPV4, HPV7, HPV27, HPV57, and HPV65 (3, 7, 10, 26, 32) . Because one of the surrogate markers for determining the etiology of common warts is the estimation of the viral load of each HPV type present in the lesion of question (7, 35, 52) , HPV2/27/57 multiplex RT-PCR can be used in combination with other quantitative HPV type-specific RT-PCRs to identify the HPV type with the highest HPV viral load and consequently the highest probability of being a "true" etiological agent of the investigated common wart.
In conclusion, the newly developed HPV2/27/57 multiplex RT-PCR, which enables simple, rapid, sensitive, and specific concurrent detection and differentiation of infections with HPV2, HPV27, and HPV57 in a single PCR reaction, is an appropriate test for use in routine clinical laboratory settings and for studies focusing on the molecular epidemiology, pathogenesis, and natural history of HPV2/27/57-related lesions.
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